SEC 13F Intelligence

Managers / Q4 2023 · view latest →

SECTORAL ASSET MANAGEMENT INC

CIK 0001274413 · 1010 SHERBROOKE ST., WEST, SUITE 1610, MONTREAL, A8, H3A 2R7 · 514 849 8777

Reported Value
$232M
Q4 2023
Positions
104
Filings on Record
30
2019–present window
Filed
Feb 14, 2024
original filing

Summary

Sectoral Asset Management Inc reported $232M in U.S.-listed holdings across 104 positions for Q4 2023.

Its largest position, LLY, represents 6.7% of the portfolio.

Compared with Q3 2023, the fund opened 10 new positions and exited 29.

Portfolio Metrics

Turnover
+12.8%
vs prior filed quarter
Top-10 Concentration
+35.1%
share of reported value
Largest Position
+6.7%
Lilly Eli
New / Exited
10 / 29
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $736MQ4 ’18Q1 ’19: $831MQ2 ’19: $836MQ3 ’19: $580MQ4 ’19: $670MQ4 ’19Q1 ’20: $521MQ2 ’20: $1.1BQ3 ’20: $1.2BQ4 ’20: $1.4BQ4 ’20Q1 ’21: $1.3BQ2 ’21: $1.2BQ3 ’21: $1.2BQ4 ’21: $664MQ4 ’21Q1 ’22: $563MQ2 ’22: $496MQ3 ’22: $508MQ4 ’22: $517MQ4 ’22Q1 ’23: $520MQ2 ’23: $600MQ3 ’23: $514MQ4 ’23: $232MQ4 ’23Q1 ’24: $254MQ2 ’24: $246MQ3 ’24: $169MQ4 ’24: $150MQ4 ’24Q1 ’25: $128MQ2 ’25: $151MQ3 ’25: $162MQ4 ’25: $125MQ4 ’25Q1 ’26: $121Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 91.9%Other: 3.8%ADR: 3.5%ETP: 0.8%
  • Common Stock · 91.9% · $214M
  • Other · 3.8% · $9M
  • ADR · 3.5% · $8M
  • ETP · 0.8% · $2M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
EWTXEDGEWISE THERAPEUTICNEW+327.8K327.8K+$4M$4M
FDMT4D MOLECULAR THERANEW+142.5K142.5K+$3M$3M
TVTXTRAVERE THERAPEUTICSNEW+274.6K274.6K+$2M$2M
ACELYRIN INCNEW+325.5K325.5K+$2M$2M
SNDXSYNDAX PHARMACEUTINEW+92.1K92.1K+$2M$2M
QUREUNIQURE N.V.NEW+292.6K292.6K+$2M$2M
ALTALTIMMUNE INCNEW+170.8K170.8K+$2M$2M
GRPHGRAPHITE BIO INCNEW+441.8K441.8K+$1M$1M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2023

104 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1LLYLILLY ELI & COhistory →COM6.67%$15M26.6K
2UNHUNITEDHEALTH GRP INChistory →COM4.29%$10M18.9K
3MRKMERCK & CO INChistory →COM3.73%$9M79.5K
4JNJJOHNSON & JOHNSONhistory →COM3.63%$8M53.9K
5AMGNAMGEN INChistory →COM3.56%$8M28.7K
6ABTABBOTT LABShistory →COM3.27%$8M69.0K
7ABBVABBVIE INChistory →COM3.09%$7M46.3K
8PFEPFIZER INChistory →COM2.35%$5M189.4K
9BSXBOSTON SCIENTIFIChistory →COM2.28%$5M91.5K
10MLYSMINERALYS THERAPEUTIhistory →COM2.24%$5M605.6K
11BMRNBIOMARIN PHARMAC INChistory →COM2.08%$5M50.1K
12TMOTHERMO FISHER SCIhistory →COM2.06%$5M9.0K
13ALNYALNYLAM PHARMACUETCLhistory →COM1.87%$4M22.6K
14BIIBBIOGEN INChistory →COM1.76%$4M15.8K
15IQVIQVIA HOLDINGS INChistory →COM1.65%$4M16.6K
16ARGXARGENX SEhistory →SPN ADR1.64%$4M10.0K
17HUMHUMANA INChistory →COM1.62%$4M8.2K
18VRTXVERTEX PHARMACEUTICLhistory →COM1.62%$4M9.2K
19DXCMDEXCOM INChistory →COM1.57%$4M29.4K
20EWTXEDGEWISE THERAPEUTIChistory →COM1.54%$4M327.8K
21DHRDANAHER CORPhistory →COM1.49%$3M15.0K
22REGNREGENERON PHARMCTCLShistory →COM1.45%$3M3.8K
23GILDGILEAD SCIENCES INChistory →COM1.43%$3M40.9K
24MDTMEDTRONIC PLChistory →SHS1.42%$3M40.1K
25ANNXANNEXON INChistory →COM1.27%$3M650.9K
26ICLRICON PLChistory →SHS1.24%$3M10.2K
27FDMT4D MOLECULAR THERAhistory →COM1.24%$3M142.5K
28PODDINSULET CORPhistory →COM1.21%$3M12.9K
29ARVNARVINAS INChistory →COM1.17%$3M66.0K
30SUTRO BIOPHARMA INCOM1.15%$3M623.7K
31REPLREPLIMUNE GROUP INChistory →COM1.11%$3M305.4K
32TVTXTRAVERE THERAPEUTICShistory →COM1.06%$2M274.6K
33GDRXGOODRX HLDGS INChistory →COM1.05%$2M364.0K
34ACELYRIN INCCOM1.05%$2M325.5K
35ITEOS THERAPEUTICSCOM1.04%$2M220.1K
36AMICUS THERAPEUTICSCOM0.96%$2M156.8K
37OPCHOPTION CARE HEALTHCOM0.93%$2M64.0K
38PMVPPMV PHARMACEUTICALSCOM0.92%$2M686.0K
39PRVAPRIVIA HEALTH GROUPCOM0.90%$2M90.3K
40SRPTSAREPTA THERAPEUTICSCOM0.89%$2M21.5K
41ALLAKOS INCCOM0.88%$2M752.4K
42AXONICS INCCOM0.88%$2M32.8K
43SNDXSYNDAX PHARMACEUTICOM0.86%$2M92.1K
44CNMDCONMED CORPCOM0.85%$2M18.1K
45QUREUNIQURE N.V.SHS0.85%$2M292.6K
46SPRYARS PHARMACEUTICALSCOM0.84%$2M354.6K
47ALTALTIMMUNE INCCOM0.83%$2M170.8K
48VERAVERA THERAPEUTICSCL A0.82%$2M124.2K
49EYPTEYEPOINT PHARMACOM0.81%$2M81.2K
50RCUSARCUS BIOSCIENCESCOM0.80%$2M97.4K
51XBISPDR SER TRS&P BIOTECH0.79%$2M20.4K
52MLTXMOONLAKE IMMUNOTHERACLASS A0.78%$2M30.0K
53AZNNASTRAZENECASPN ADR0.76%$2M26.1K
54BIOATLA INCCOM0.75%$2M706.1K
55PRTAPROTHENA CORP PLCSHS0.73%$2M46.8K
56EWEDWARDS LIFESCIENCECOM0.72%$2M21.9K
57VSTMVERASTEM INCCOM0.71%$2M203.3K
58IOVAIOVANCE BIOTHERAPEUTCOM0.70%$2M198.8K
59MRNAMODERNA INCCOM0.69%$2M16.1K
60TURNSTONE BIOLOGICSCOM0.57%$1M517.6K
61AMLXAMYLYX PHARMACEUTICCOM0.53%$1M84.1K
62GRPHGRAPHITE BIO INCCOM0.50%$1M441.8K
63EFFECTOR THERAPEUTCSCOM0.48%$1M2.38M
64ILMNILLUMINA INCCOM0.40%$918,9846.6K
65KARUNA THERAPEUTICSCOM0.30%$707,4002.2K
66SNYSANOFISPN ADR0.30%$700,69614.1K
67ONCBEIGENE LIMITEDSPN ADR0.29%$676,7113.8K
68INCYINCYTE CORPORATIONCOM0.27%$634,49310.1K
69UTHRUNITED THERAPEUTICSCOM0.27%$618,9902.8K
70NBIXNEUROCRINE BIOSCIENCCOM0.25%$585,6734.4K
71CYTKCYTOKINETICS INCCOM0.25%$585,5157.0K
72RPRXROYALTY PHARMA PLCSHS CLASS A0.25%$577,81120.6K
73ASNDASCENDIS PHARMA A SSPN ADR0.24%$559,3444.4K
74FUSION PHARMACEUTICOM0.24%$550,62457.3K
75INTRA CELLULAR THERACOM0.23%$531,4207.4K
76IMMUNOGEN INCCOM0.23%$530,61617.9K
77BBIOBRIDGEBIO PHARMA INCCOM0.23%$522,99313.0K
78PCVXVAXCYTE INCCOM0.22%$505,5408.1K
79JAZZJAZZ PHARMA PLCSHS USD0.22%$503,5624.1K
80ACADACADIA PHARMACEUTCLSCOM0.20%$471,52915.1K
81INSMINSMED INCCOM0.18%$428,00313.8K
82ALKSALKERMES PLCSHS0.18%$425,25415.3K
83MEDPMEDPACE HOLDINGSCOM0.18%$420,2531.4K
84ROIVROIVANT SCIENCES LTDSHS0.18%$409,41236.5K
85RVMDREVOLUTION MEDICINCOM0.17%$393,20313.7K
86BNTXBIONTECH SESPN ADR0.17%$393,1373.7K
87MIRATI THERAPEUTICSCOM0.16%$380,3486.5K
88RCKTROCKET PHARMACEUTICACOM0.16%$368,03212.3K
89EXELEXELIXIS INCCOM0.14%$335,62014.0K
90IONSIONIS PHARMACEUTICALCOM0.14%$327,8236.5K
91RDYDR REDDYS LABS LTDADR0.13%$313,1104.5K
92APELLIS PHARMACEUTICCOM0.13%$312,4695.2K
93NTLAINTELLIA THERAPEUTCOM0.12%$283,5579.3K
94MDGLMADRIGAL PHARMACEUTICOM0.12%$277,8871.2K
95DNLIDENALI THERAPEUTICSCOM0.12%$276,42612.9K
96OLMAOLEMA PHARMACEUTICALCOM0.12%$269,79719.2K
97ARWRARROWHEAD PHARMACEUTCOM0.11%$250,3698.2K
98BLUEPRINT MEDICINESCOM0.10%$227,8332.5K
99HALOHALOZYME THERAPEUTICCOM0.10%$222,8696.0K
100LEGNLEGEND BIOTECH CORPSPN ADR0.08%$180,5103.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$121M77May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$125M74Feb 9, 202613F-HRchanges · EDGAR ↗
Q3 2025$162M82Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$151M94Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$128M84May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$150M86Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$169M90Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$246M97Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$254M92May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$232M104Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$514M123Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$600M121Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$520M118May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$517M120Feb 10, 202313F-HRchanges · EDGAR ↗
Q3 2022$508M109Nov 10, 202213F-HRchanges · EDGAR ↗
Q2 2022$496M112Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$563M106May 10, 202213F-HRchanges · EDGAR ↗
Q4 2021$664M108Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.2B127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.2B127Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.3B113May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.4B97Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.2B88Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.1B191Aug 13, 202013F-HRchanges · EDGAR ↗
Q1 2020$521M65May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$670M65Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$580M63Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$836M92Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$831M106May 14, 201913F-HRchanges · EDGAR ↗
Q4 2018$736M104Feb 12, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.